Platinum Industries Ltd has announced its entry into the life sciences sector through the formation of its wholly owned subsidiary, Rivadu Lifesciences Pvt. Ltd, marking a major strategic expansion aimed at building a research-driven and globally scalable presence in high-value healthcare segments. The company has appointed Dr Abhigyan Upadhyay to lead the new enterprise, bringing more than 25 years of international leadership experience across life sciences, diagnostics, regulated manufacturing, and research-focused businesses.
The move signals Platinum Industries’ broader ambition to extend its expertise in specialty chemistry into areas directly linked to human health and wellbeing. The company said the expansion aligns with its long-term vision of combining innovation, quality, and responsible practices to create value-driven solutions for emerging global markets.
Dr Upadhyay has held leadership positions across multiple international life sciences businesses and has been involved in driving operational transformation, business expansion, and strategic growth initiatives. During the COVID-19 pandemic, he also contributed to clinical trials and research-led programs focused on critical healthcare applications.
Commenting on the development, Krishna Dushyant Rana said the company’s entry into life sciences is a carefully planned step towards applying its strengths in chemistry to sectors that create meaningful impact on healthcare outcomes. He stated that the business will be developed through a disciplined and phased approach focused on innovation, research capabilities, and long-term scalability. According to him, Dr Upadhyay’s experience and strategic understanding of the global life sciences ecosystem will help build a strong operational and growth framework for the new venture.
Dr Upadhyay said the life sciences industry is increasingly driven by the ability to convert scientific expertise into reliable and high-quality outcomes. He noted that the company will focus on identifying strategic opportunities, collaborating with partners, and gradually building a portfolio of innovative products across research-led and high-value segments.
Initially, Rivadu Lifesciences will focus on active pharmaceutical ingredients (APIs) and intermediates, leveraging Platinum Industries’ execution capabilities and market reach to establish a scalable business model. The company also plans to strengthen its presence in key global markets including the United States, Europe, the Middle East, and Asia.
